Clinical trials have demonstrated that alectinib is highly effective in treating ALK-positive NSCLC. In comparison to crizotinib, alectinib has shown a higher response rate and longer progression-free survival. Additionally, it has proven efficacy in crossing the blood-brain barrier, making it effective against brain metastases, which are common in ALK-positive NSCLC patients.